Search results
Results From The WOW.Com Content Network
AstraZeneca claimed the deal undervalued the company. [15] 4 2014 Pfizer: Astra Zeneca: 99 127 AstraZeneca claimed the deal undervalued the company. [16] 5 1999 Pfizer: Warner–Lambert: 82.4 151 Pfizer made a hostile bid, just after the announcement of a $72 billion deal with Wyeth, the eventual purchase price would be in excess of $90 billion ...
Cathay Drug is recognized as one of the fastest-growing pharmaceutical companies in the Philippines. In 2012, it was included in the Top 20 Leading Philippine Pharmaceutical Companies based on Value in the Philippine Pharmaceutical Industry Audit [2] for ethical segment by IMS. It was also ranked second among national pharmaceutical companies ...
The Federal Trade Commission had its first win earlier this week in its crusade to block drug company deals: Sanofi on Monday ended its up-to-$735 million licensing deal with Maze Therapeutics.
The biggest money market scam ever committed in India, amounting to approximately ₹ 5,000 crores. The main perpetrator of the scam was a stock and money market broker Harshad Mehta. It was a systematic stock scam using fake bank receipts and stamp paper that caused the Indian stock market to crash. The scam exposed the inherent loopholes of ...
Humulin saw the biggest price hike, rising 1,070.1% from $67 in 2012 to $1,512 in 2022. Adriana Belmonte is a reporter and editor covering politics and health care policy for Yahoo Finance.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Shares of Mallinckrodt were up 10% after the company announced that it's buying Cadence for $1.3 billion. Shares of Cadence performed even better, up about 25% on the buyout news. The catalyst for ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify